Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
COMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CACOMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
Longevity Prediction Market

When will Longevity Escape Velocity be reached?

approved openMultiple choicePrognosis made 2 Jul 2026Voting closes 1 Nov 20260 traders0.00 cr volume

Chance it happens

80%
Happens 80%No 10%Other 10%

Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.

Outcomes

By end of 202710.0%
202810.0%
2029–203010.0%
2031–203410.0%
2035–204210.0%
2043–205810.0%
2059–209010.0%
2091–210010.0%
Never (after 2100)10.0%
Other10.0%

Resolution criteria

Longevity Escape Velocity (LEV) = the point at which remaining life expectancy rises by more than one year for each calendar year of research and medical progress. Resolves on the year that condition is first credibly judged to be met. Resolution horizon: 2100-12-31. Source: consensus of demographic / longevity-science reporting.

Evidence & context

Trials, publications and reports our research found on this prognosis. Each links to the original source.

NMN.com

This is a news-style article summarizing Aubrey de Grey's views on longevity escape velocity. It directly bears on the prediction because it reports his stated timeline that LEV could be reached toward the latter part of the 2030s.

Life Biosciences

This is a news report on the FDA clearing Life Biosciences' IND for ER-100, an epigenetic partial cellular reprogramming therapy, with initial human ocular trials beginning in 2026 and possible expansion to liver disease by 2027-2028. It bears on LEV prognosis because it is concrete evidence that rejuvenation-oriented interventions are advancing from preclinical work into regulated human testing.

Harvard Medical School

This is a peer-reviewed research article on chemical reprogramming aimed at reversing cellular aging. It bears on LEV prognosis because it is direct scientific evidence about whether aging can be biologically reversed, a core prerequisite for sustained gains in life expectancy.

Longevity Escape Velocity Foundation

This is a Fight Aging! news/blog post about Aubrey de Grey launching the Longevity Escape Velocity Foundation, an organization explicitly oriented around achieving LEV. It is relevant as contextual evidence about expert-led institutional effort and expectations in longevity science, though it does not by itself establish that LEV has been reached.

Aubrey de Grey

This appears to be a conference talk by Aubrey de Grey, a prominent longevity advocate, discussing rejuvenation and longevity at ARDD2024. Expert public statements from leading figures in biogerontology are relevant to forecasting when LEV might be judged achievable, even though this is not a formal publication or clinical result.

SENS

This appears to be a social post sharing or discussing an Aubrey de Grey interview on the SENS approach and longevity escape velocity. As a prominent longevity advocate's stated view on LEV, it is directly relevant as expert-opinion evidence bearing on expected timing, though it is not a formal scientific or demographic consensus source.

Aubrey de Grey

This appears to be a commentary/interview-style article on Calum Chace's site discussing Aubrey de Grey's views on radical life extension and the possibility that public recognition of major longevity gains could arrive soon. It bears on the prognosis indirectly because de Grey is a prominent longevity advocate whose timeline expectations are relevant to forecasts about when LEV might be judged achievable, though this is opinion-oriented rather than consensus demographic reporting.

Belief over time — chance it happens

0255075100Jul 2 · 80.0% chance80.0% chance
Jul 2Jul 2

Recent trades

No trades yet.